On Wednesday, Galena Biopharma Inc (NASDAQ:GALE)’s shares inclined 1.84% to $1.66.
Galena Biopharma, Inc. (GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, recently declared the product launch for Zuplenz(R)(ondansetron) Oral Soluble Film in the United States.
Zuplenz is now accessible nationwide and is supplied in both 4 mg and 8 mg strengths. Zuplenz is clinically bioequivalent to ondansetron orally disintegrating tablets (ODT) with a safety profile equivalent to ondansetron. The novel, PharmFilm(R) oral soluble film technology utilized by Zuplenz provides for convenient delivery and several key patient benefits counting:
- Rapidly dissolves in the mouth in about 10 seconds
- Eliminates the burden of swallowing pills during emesis and in cases of oral irritation
- Does not require water to administer
- Pleasant peppermint flavor with no gritty aftertaste
- Non-sedating
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs across cancer care. Its commercial products comprise Abstral, a sublingual tablet that is used for the administration of breakthrough pain in patients with cancer; and Zuplenz, an oral soluble film for use in the prevention of chemotherapy-induced, radiotherapy-induced, and post-operative nausea and vomiting.
Pacific Ethanol Inc (NASDAQ:PEIX)’s shares dropped -0.80% to $7.45.
Pacific Ethanol, Inc. (PEIX), a leading producer and marketer of low-carbon renewable fuels in the United States, stated its financial results for the three- and six-months ended June 30, 2015.
Second quarter 2015 Financial Highlights
- Net sales of $227.6 million
- Gross profit of $6.3 million
- Operating income of $2.3 million
- EPS of $0.03
- Adjusted EBITDA of $5.4 million
- Record total gallons sold of 140.7 million
Pacific Ethanol, Inc. produces and markets low-carbon renewable fuels in the Western United States. It sells ethanol primarily to gasoline refining and distribution companies. The company also provides ethanol transportation, storage, and delivery services through third-party service providers. In addition, it markets ethanol co-products, counting wet distiller grains and syrup to dairy operators and animal feed distributors; and corn oil to poultry and biodiesel customers.
At the end of Wednesday’s trade, Cytori Therapeutics Inc (NASDAQ:CYTX)‘s shares dipped -0.17% to $0.420.
Cytori Therapeutics (CYTX) declared that enrollment has been accomplished in its US Phase IIb Osteoarthritis trial. The ACT-OA trial is a double-blind randomized, placebo-controlled trial evaluating the safety, feasibility and dosing of intraarticular administration of Cytori’s ECCO-50 cellular therapeutic in patients with knee osteoarthritis. A total of 94 patients were enrolled as of June 12, 2015.
The availability of safety and efficacy data in Q1 2016 will lead to informed decisions and talk about with the FDA regarding the study design and size of an osteoarthritis Phase III program with Cytori Cell Therapy.
Osteoarthritis is a disease of the entire joint involving the cartilage, joint lining, ligaments, and underlying bone. The breakdown of tissue leads to pain, joint stiffness and reduced function. It is the most common form of arthritis and affects an estimated 26.9 million US adults.1 Current treatments comprise physical therapy, non-steroidal anti-inflammatory medications, viscosupplement injections, and total knee replacement. The American Academy of Orthopedic Surgeon’s guidelines for the treatment of osteoarthritis of the knee noted that there were few non-surgical treatments that could be recommended2, which highlights the potential for Cytori Cell Therapy to address a large inadequately addressed medical need.
Cytori Therapeutics, Inc., a biotechnology company, develops cell therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy comprising of a heterogeneous population of specialized cells, counting stem cells for the treatment of patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence, and thermal burns combined with radiation injury.
Chimera Investment Corporation (NYSE:CIM), shares showed no change and closed at $14.23.
Chimera Investment Corporation (CIM) and Annaly Capital Administration, Inc. jointly declared that, effective recently, Chimera is internalizing its administration function. The independent directors on Chimera’s Board agreed to the internalization with Annaly in order to accelerate growth and realize cost efficiencies. Chimera will continue to be led by its key professionals counting President and Chief Executive Officer Matthew Lambiase, Chief Financial Officer Rob Colligan and Chief Investment Officer Mohit Marria. In addition, Chimera’s head of structured products, Choudhary Yarlagadda, was designated Chief Operating Officer and Phillip J. Kardis II, a partner at the law firm K&L Gates LLP, was designated General Counsel. All other personnel that focus their efforts on Chimera’s business became employees of Chimera.
Chimera Investment Corporation operates as a real estate investment trust in the United States. The company, through its auxiliaries, invests in residential mortgage-backed securities (RMBS), residential mortgage loans, commercial mortgage loans, real estate-related securities, and various other asset classes. Its targeted asset classes comprise non-agency RMBS, such as investment-grade and non-investment grade classes; agency RMBS; interest-only RMBS; and first or second lien loans secured by multifamily properties, mixed residential or other commercial properties, retail properties, office properties, and industrial properties.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
